Compare AstraZeneca plc (AZN) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs ProShares Ultra QQQ ETF — how do they compare? AstraZeneca plc trades at $157.44 (market cap $248.14B), while ProShares Ultra QQQ ETF trades at $92.51. The key difference: AstraZeneca plc pays a 2.01% dividend while ProShares Ultra QQQ ETF pays none, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | QLD | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $209.48 | $100.53 |
52-Week Low | $147.06 | $57.16 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
QLD, the ProShares Ultra QQQ ETF, trades at $92.56, up 1.01% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF, offering 2x daily leverage on the Nasdaq-100, has delivered over 10,000% total return since inception, though it carries amplified risk. Recent institutional buying includes 180 Wealth Advisors increasing its position by 29.4% in Q2 2026, signaling confidence in tech exposure.
The outlook for QLD hinges on tech sector performance, with AI optimism and easing geopolitical tensions as tailwinds. However, leveraged ETF structure risks decay in volatile markets, and a 63.80% historical drawdown underscores volatility. Investors seeking aggressive tech growth may find opportunity, but must tolerate significant swings; diversification and risk management are critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
